Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
Wed, 12.08.2026
Masterflex SE
Masterflex increases revenue and earnings in the first half of 2026 – profitability further improved despite start-up investments – guidance confirmed
Group revenue increased by 1.7% to EUR 54.3 million despite a challenging environment (previous year: EUR 53.4 million)
Operating Group EBIT increased to EUR 8.0 million (previous year: EUR 7.9 mil [ … ]
Wed, 12.08.2026
Douglas AG
Q3 (April – June 2026) & 9M 2025/2026 (October 2025 – June 2026)
DOUGLAS Group reports third quarter results in line with expectations and confirms full-year guidance
Performance: Q3 sales -2.0% to 987.8 million euros, adjusted EBITDA margin: 12.9% (adjusted EBITDA of 127.5 million euros); net leverage: 3.1x as of 30 June 2026 (2.2x before le [ … ]
Wed, 12.08.2026
Sensirion Holding AG
Sensirion Holding AG
/ Key word(s): Miscellaneous
Sensirion’s SGM5304 gas meter module successfully achieves EN 17526 certificatio
12.08.2026 / 07:30 CET/CEST
Media Release
12.08.2026, Sensirion AG, 8712 Staefa, Switzerland
The SGM5304 gas meter module has successfully completed EN 17526 certification at NMi, ena [ … ]
Wed, 12.08.2026
Hannover Rück SE
Hannover Re generates very good half-year result and remains on track to achieve full-year guidance
Group net income up by 7.0% to EUR 1.4 billion
Reinsurance revenue (gross) on the Group level grows by 0.7% adjusted for exchange rate effects
Return on equity reaches 21.5%
Large losses in property and casualty reinsurance below expected level [ … ]
Wed, 12.08.2026
INDUS Holding AG
INDUS H1: Growth across all three segments
Revenue up 15.4% at the six-month mark, adjusted EBITA rises to EUR 123.5 million
Adjusted EBITA margin increases significantly to 12.8%
Special effect from ongoing extraordinary development in Materials Solutions segment
Higher incoming orders in all segments
Guidance raised
Bergisch Gladbach, 12 Aug [ … ]
Wed, 12.08.2026
Deutsche Konsum Real Estate AG
Deutsche Konsum Real Estate AG publishes quarterly statement for the first nine months of the 2025/2026 financial year
Implementation of the restructuring plan: Property sales of around EUR 78 million completed since the start of the restructuring process; additional purchase agreements worth EUR 16 million signed
Financing structure further impr [ … ]
Wed, 12.08.2026
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma with strong third quarter and on track for planned growth
Revenue growth in Q3 of 8.3% at constant currencies (reported: 10.0%); 9M revenue of EUR 769.8 million 4.4% above the previous year's level at constant currencies (reported: 4.1%)
EBITDA margin of 26.8% in Q3; 9M margin at 26.7% (9M 2025: 28.9%)
Revenue share of high-margin [ … ]
Wed, 12.08.2026
thyssenkrupp nucera AG & Co. KGaA
thyssenkrupp nucera Doubles Order Intake in the First Nine Months of 2025/2026
Order intake rose by 29 percent in the third quarter, bringing new business in the first nine months of fiscal year 2025/2026 to nearly double (+96%)
Moeve also secures a service package for operating the 300-MW electrolyzer for Southern Europe’s largest hydrogen proje [ … ]
Wed, 12.08.2026
Grand City Properties S.A.
THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF APPLICABLE LAWS OR REGULATIONS
GRAND CITY PROPERTIES S.A. ANNOUNCES H1 2026 RESULTS WITH ROBUST OPERATIONS CONFIRMI [ … ]
Wed, 12.08.2026
Formycon AG
Press Release // August 12, 2026
Formycon reports key operational achievements in the first half of 2026 and significantly improves financial results year-on-year
First-half financial results significantly improved year-on-year, with a substantial increase in revenue – 2026 guidance confirmed
Successful completion of FYB206 clinical developmen [ … ]
